drug resistance

You have access
Combination Treatment With Sorafenib and Everolimus Regresses a Doxorubicin-resistant Osteosarcoma in a PDOX Mouse Model
TAKASHI HIGUCHI, NORIHIKO SUGISAWA, KENTARO MIYAKE, HIROMICHI OSHIRO, NORIO YAMAMOTO, KATSUHIRO HAYASHI, HIROAKI KIMURA, SHINJI MIWA, KENTARO IGARASHI, ZOEY KLINE, PAIGE BELT, SANT P. CHAWLA, MICHAEL BOUVET, SHREE RAM SINGH, HIROYUKI TSUCHIYA and ROBERT M. HOFFMAN

Anticancer Research September 2019, 39 (9) 4781-4786; DOI: https://doi.org/10.21873/anticanres.13662
You have access
Anti-parasitic Drug Ivermectin Exhibits Potent Anticancer Activity Against Gemcitabine-resistant Cholangiocarcinoma In Vitro
KITTI INTUYOD, CHARIYA HAHNVAJANAWONG, PORNTIP PINLAOR and SOMCHAI PINLAOR

Anticancer Research September 2019, 39 (9) 4837-4843; DOI: https://doi.org/10.21873/anticanres.13669
You have access
Co-treatment With HIV Protease Inhibitor Nelfinavir Greatly Increases Late-phase Apoptosis of Drug-resistant KBV20C Cancer Cells Independently of P-Glycoprotein Inhibition
JI YEONG KIM, YOO JUNG PARK, BYUNG-MU LEE and SUNGPIL YOON

Anticancer Research July 2019, 39 (7) 3757-3765; DOI: https://doi.org/10.21873/anticanres.13524
You have access
Tyrosine Kinase Inhibitors Imatinib and Erlotinib Increase Apoptosis of Antimitotic Drug-resistant KBV20C Cells Without Inhibiting P-gp
JI YEONG KIM, HYUNG SIK KIM and SUNGPIL YOON

Anticancer Research July 2019, 39 (7) 3785-3793; DOI: https://doi.org/10.21873/anticanres.13527
You have access
AS602801 Sensitizes Ovarian Cancer Stem Cells to Paclitaxel by Down-regulating MDR1
MASAHIRO YAMAMOTO, SHUHEI SUZUKI, KEITA TOGASHI, TOMOMI SANOMACHI, SHIZUKA SEINO, CHIFUMI KITANAKA and MASASHI OKADA

Anticancer Research February 2019, 39 (2) 609-617; DOI: https://doi.org/10.21873/anticanres.13154
You have access
Identification of Genomic Alterations Acquired During Treatment With EGFR-TKIs in Non-small Cell Lung Cancer
NAOKI KUBO, TAISHI HARADA, YOSHIMASA SHIRAISHI, KANAME NOSAKI, NORIAKI NAKAGAKI, MASAFUMI TAKESHITA, HIROSHI OUCHI, EIJI IWAMA, KENTARO TANAKA, ISAMU OKAMOTO, HIROYUKI SASAKI and YOICHI NAKANISHI

Anticancer Research February 2019, 39 (2) 671-677; DOI: https://doi.org/10.21873/anticanres.13162
You have access
AS602801, an Anticancer Stem Cell Candidate Drug, Reduces Survivin Expression and Sensitizes A2780 Ovarian Cancer Stem Cells to Carboplatin and Paclitaxel
MASAHIRO YAMAMOTO, SHUHEI SUZUKI, KEITA TOGASHI, TOMOMI SANOMACHI, SHIZUKA SEINO, CHIFUMI KITANAKA and MASASHI OKADA

Anticancer Research December 2018, 38 (12) 6699-6706; DOI: https://doi.org/10.21873/anticanres.13038
You have access
Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC
SILVANA GIACINTI, GIULIA POTI, MICHELA ROBERTO, SERENA MACRINI, MARIA BASSANELLI, FRANCESCA DI PIETRO, ANNA MARIA ASCHELTER, ANNA CERIBELLI, ENZO MARIA RUGGERI and PAOLO MARCHETTI

Anticancer Research November 2018, 38 (11) 6029-6039; DOI: https://doi.org/10.21873/anticanres.12953
You have access
P-gp Inhibition by the Anti-psychotic Drug Pimozide Increases Apoptosis, as well as Expression of pRb and pH2AX in Highly Drug-resistant KBV20C Cells
JI YEONG KIM, YUJIN PARK, BYUNG-MU LEE, HYUNG SIK KIM and SUNGPIL YOON

Anticancer Research October 2018, 38 (10) 5685-5692; DOI: https://doi.org/10.21873/anticanres.12905
You have access
Low Doses of the Anti-psychotic Drug Aripiprazole Have Strong P-gp-inhibitory Activity and Sensitize Anti-mitotic Drug-resistant Cancer Cells
JI YEONG KIM, IN HWAN TAE, BYUNG-MU LEE, HYUNG SIK KIM and SUNGPIL YOON

Anticancer Research September 2018, 38 (9) 5101-5108; DOI: https://doi.org/10.21873/anticanres.12830

Main menu

User menu

Search

drug resistance

Pages